Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Duexis in patients requiring long-term NSAIDs
NCT00984815Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibuprofen + famotidine in osteoarthritis (OA), rheumatoid arthritis (RA), chronic low back pain (CLBP) and 2 more, sponsored by Amgen. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 54 weeks. Started Sep 2009; status: completed.
02
Drugs
ibuprofen + famotidine
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)chronic low back pain (CLBP)complex regional pain syndrome (CRPS)chronic myofascial pain (CMP)
Beyond the preview
Go deeper on NCT00984815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984815.